GANX

+ Watchlist + Portfolio

Gain Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.07
52-Week Range: $1.53 – $4.34
Market Cap: $86.41M
P/E (TTM): —
EPS (TTM): -0.50
Dividend Yield: —

Advanced Metrics

Price/Book: 7.59
PEG Ratio: —
Return on Equity: -268.30%
Return on Assets: -95.51%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 4.36
Debt/Equity: 0.05
Total Debt: $609.87K
Free Cash Flow: $-11.14M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $77.87M

GANX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$140.11K	$55.18K	$0.00	$0.00
Research & Development	$8.38M	$11.52M	$10.79M	$10.21M
Selling, General & Admin	$9.54M	$10.79M	$9.56M	$8.50M
Operating Expenses	$17.92M	$22.31M	$20.35M	$18.71M
Operating Income	-$17.78M	-$22.25M	-$20.35M	-$18.71M
EBITDA	-$17.71M	-$22.17M	-$20.27M	-$18.62M
Pretax Income	-$17.50M	-$22.19M	-$19.87M	-$19.30M
Income Tax	$92.98K	$79.28K	$536.82K	$861.12K
Net Income	-$17.59M	-$22.27M	-$20.41M	-$20.16M
Diluted EPS	-1.48	-1.71	-0.89	-0.61
Diluted Shares	11.88M	13.01M	22.88M	32.97M

GANX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$7.31M	$11.79M	$10.39M	$20.84M
Receivables	$191.31K	$242.58K	$765.76K	$802.69K
Current Assets	$21.09M	$17.78M	$11.60M	$22.24M
Total Assets	$24.10M	$18.61M	$12.12M	$22.82M
Current Liabilities	$4.13M	$4.95M	$3.91M	$3.35M
Long-Term Debt	$495.26K	$449.05K	$328.33K	$300.08K
Total Debt	$1.27M	$1.03M	$653.01K	$732.07K
Total Liabilities	$5.22M	$6.03M	$4.78M	$4.25M
Retained Earnings	-$38.52M	-$60.78M	-$81.19M	-$101.36M
Shareholders' Equity	$18.88M	$12.58M	$7.34M	$18.56M
Working Capital	$16.97M	$12.83M	$7.69M	$18.88M

GANX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$14.69M	-$18.87M	-$18.87M	-$18.47M
Capital Expenditure	-$118.95K	-$15.36K	-$22.49K	—
Free Cash Flow	-$14.81M	-$18.88M	-$18.90M	-$18.47M
Depreciation & Amortisation	$64.17K	$83.58K	$84.07K	$94.05K
Stock-Based Compensation	$1.53M	$3.26M	$2.39M	$1.80M
Investing Cash Flow	-$14.77M	$10.22M	$4.98M	$0.00
Financing Cash Flow	-$78.77K	$12.64M	$13.01M	$28.45M
Net Change in Cash	-$29.55M	$4.00M	-$884.24K	$9.98M

GANX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$2.26M	$2.76M	$2.85M	$2.35M	$2.76M
Selling, General & Admin	$2.11M	$2.33M	$1.94M	$2.12M	$2.59M
Operating Expenses	$4.37M	$5.09M	$4.79M	$4.47M	$5.35M
Operating Income	-$4.37M	-$5.09M	-$4.79M	-$4.47M	-$5.35M
EBITDA	-$4.35M	-$5.07M	-$4.76M	-$4.44M	-$5.33M
Pretax Income	-$4.43M	-$5.67M	-$4.74M	-$4.47M	-$5.43M
Income Tax	$100.51K	$141.21K	$549.29K	$70.12K	$183.07K
Net Income	-$4.53M	-$5.81M	-$5.28M	-$4.54M	-$5.61M
Diluted EPS	-0.16	-0.19	-0.15	—	-0.13
Diluted Shares	28.69M	30.34M	35.00M	—	42.23M

GANX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$9.07M	$6.69M	$8.81M	$20.84M	$16.54M
Receivables	$886.62K	$1.41M	$788.61K	$802.69K	$994.61K
Current Assets	$11.15M	$9.31M	$10.52M	$22.24M	$18.22M
Total Assets	$11.62M	$9.83M	$10.97M	$22.82M	$18.74M
Current Liabilities	$5.03M	$5.20M	$4.17M	$3.35M	$3.89M
Long-Term Debt	$314.48K	$325.36K	$298.80K	$300.08K	$273.26K
Total Debt	$606.86K	$680.64K	$605.28K	$732.07K	$672.30K
Total Liabilities	$5.84M	$6.14M	$5.06M	$4.25M	$4.73M
Retained Earnings	-$85.72M	-$91.53M	-$96.82M	-$101.36M	-$106.96M
Shareholders' Equity	$5.78M	$3.70M	$5.91M	$18.56M	$14.01M
Working Capital	$6.12M	$4.11M	$6.35M	$18.88M	$14.34M

GANX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$3.82M	-$5.10M	-$4.93M	-$4.62M	-$4.73M
Free Cash Flow	-$3.82M	-$5.10M	-$4.93M	-$4.62M	-$4.73M
Depreciation & Amortisation	$20.66K	$22.33K	$22.82K	$28.24K	$21.30K
Stock-Based Compensation	$419.50K	$522.02K	$460.00K	$401.67K	$403.51K
Investing Cash Flow	$0.00	$0.00	$0.00	$0.00	—
Financing Cash Flow	$2.40M	$2.47M	$7.03M	$16.55M	$404.32K
Net Change in Cash	-$1.42M	-$2.63M	$2.11M	$11.93M	-$4.32M

Market Snapshot

About

Gain Therapeutics, Inc. is a biotechnology company focused on discovering and developing novel small molecule therapeutics for rare and common diseases. The company's proprietary drug discovery platform, Magellan, uses computational methods and structural biology to identify allosteric binding sites on disease-related proteins. Gain Therapeutics is developing treatments for lysosomal storage disorders, including Gaucher disease and Parkinson's disease. The company's approach aims to create first-in-class or best-in-class oral therapies that can modulate protein function and restore cellular homeostasis.